The novel MAO-B inhibitors developed in this study are expected to overcome the limitations of existing drugs, such as improved efficacy, reduced side effects, and enhanced selectivity, and provide new options for the treatment of neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. The gene discussed is MAOB; the disease is neurodegenerative disease.